Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials
Julian W Sacre, Dianna J Magliano, Jonathan E Shaw
DIABETES CARE | AMER DIABETES ASSOC | Published : 2020
BACKGROUND: Emerging evidence points to heart failure as being a common first presentation of cardiovascular (CV) disease in type 2 diabetes. PURPOSE: The purpose of this study was to determine whether hospitalization for heart failure (HHF) occurs more or less frequently than major adverse CV events (MACE) in people with type 2 diabetes. DATA SOURCES: Placebo arms of CV outcomes trials in type 2 diabetes were included. STUDY SELECTION: Sixteen CV outcomes trials were selected, including five dipeptidyl peptidase 4 inhibitor trials, seven glucagon-like peptide 1 receptor agonist trials, and four sodium-glucose cotransporter 2 inhibitor trials. DATA EXTRACTION: We extracted incidence rates of..View full abstract
Awarded by National Health and Medical Research Council of Australia
This work was supported by the National Health and Medical Research Council of Australia(APP1107361toD.J.M. andAPP1173952to J.E.S.) and the State Government of Victoria Operational Infrastructure Support Program.